ALTEOGEN Inc - Asset Resilience Ratio

Latest as of September 2025: 51.30%

ALTEOGEN Inc (196170) has an Asset Resilience Ratio of 51.30% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of ALTEOGEN Inc for a breakdown of total debt and financial obligations.

Liquid Assets

₩328.05 Billion
≈ $222.32 Million USD Cash + Short-term Investments

Total Assets

₩639.48 Billion
≈ $433.36 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2014–2024)

This chart shows how ALTEOGEN Inc's Asset Resilience Ratio has changed over time. See what is ALTEOGEN Inc's book value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down ALTEOGEN Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 196170 market cap overview.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents ₩0.00 0%
Short-term Investments ₩328.05 Billion 51.3%
Total Liquid Assets ₩328.05 Billion 51.30%

Asset Resilience Insights

  • Very High Liquidity: ALTEOGEN Inc maintains exceptional liquid asset reserves at 51.30% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company has significant short-term investments, indicating active treasury management.

ALTEOGEN Inc Industry Peers by Asset Resilience Ratio

Compare ALTEOGEN Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Argen-X
F:1AE
Biotechnology 25.67%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.21%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.48%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 70.49%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%

Annual Asset Resilience Ratio for ALTEOGEN Inc (2014–2024)

The table below shows the annual Asset Resilience Ratio data for ALTEOGEN Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 45.29% ₩185.25 Billion
≈ $125.54 Million
₩409.01 Billion
≈ $277.18 Million
+2.10pp
2023-12-31 43.19% ₩110.61 Billion
≈ $74.96 Million
₩256.10 Billion
≈ $173.56 Million
-8.76pp
2022-12-31 51.95% ₩127.54 Billion
≈ $86.43 Million
₩245.49 Billion
≈ $166.37 Million
-25.64pp
2021-12-31 77.59% ₩202.00 Billion
≈ $136.90 Million
₩260.34 Billion
≈ $176.43 Million
-6.36pp
2020-12-31 83.95% ₩133.66 Billion
≈ $90.58 Million
₩159.21 Billion
≈ $107.89 Million
+11.87pp
2019-12-31 72.08% ₩61.98 Billion
≈ $42.00 Million
₩85.98 Billion
≈ $58.27 Million
-0.09pp
2018-12-31 72.17% ₩51.52 Billion
≈ $34.91 Million
₩71.38 Billion
≈ $48.37 Million
-3.23pp
2017-12-31 75.40% ₩32.43 Billion
≈ $21.98 Million
₩43.01 Billion
≈ $29.15 Million
-2.43pp
2016-12-31 77.82% ₩37.32 Billion
≈ $25.29 Million
₩47.95 Billion
≈ $32.49 Million
+29.84pp
2015-12-31 47.99% ₩18.90 Billion
≈ $12.81 Million
₩39.39 Billion
≈ $26.69 Million
+9.39pp
2014-12-31 38.60% ₩14.65 Billion
≈ $9.93 Million
₩37.96 Billion
≈ $25.72 Million
--
pp = percentage points

About ALTEOGEN Inc

KQ:196170 Korea Biotechnology
Market Cap
$13.36 Billion
₩19.71 Trillion KRW
Market Cap Rank
#1772 Global
#43 in Korea
Share Price
₩368500.00
Change (1 day)
-3.03%
52-Week Range
₩317500.00 - ₩559000.00
All Time High
₩559000.00
About

ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the d… Read more